Systemic lupus erythematosus: When to consider and management options

Australian Family Physician

Volumn 42, Issue 10, 2013, Pages 696-700

  Apostolopoulos, Diane ^a   Hoi, Alberta Yik Bun ^a  

^a SOUTHERN HEALTH   (Australia)

Author keywords

Discoid; Lupus erythematosus; Systemic

Indexed keywords

ANTINUCLEAR ANTIBODY; ANTIRHEUMATIC AGENT; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; IMMUNOSUPPRESSIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID;

ANEMIA; ARTHRITIS; ARTICLE; BLOOD; CASE REPORT; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; METABOLISM; RASH; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANEMIA; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, ANTINUCLEAR; ANTIRHEUMATIC AGENTS; ARTHRITIS; COMPLEMENT C3; COMPLEMENT C4; EXANTHEMA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; STEROIDS;

EID: 84886922944     PISSN: 03008495     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Gaubitz M. Epidemiology of connective tissue disorders. Rheumatology (Oxford) 2006;45(Supplement 3):iii3-4.
2. Chakravarty EF, Bush TM, Manzi S, Clarke AE, Ward MM. Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: estimates obtained using hospitalization data. Arthritis Rheum 2007;56:2092-94.
3. Pons-Estel GJ, Alarcón GS, Scofield L, Reinlib L, Cooper GS. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum 2010;39:257-68.
4. Grennan DM, Bossingham D. Systemic lupus erythematosus (SLE): different prevalences in different populations of Australian aboriginals. Aust N Z J Med 1995;25:182-83.
5. Connelly K, Morand EF, Hoi AY. Asian ethnicity in systemic lupus erythematosus: an Australian perspective. Intern Med J 2013;43:618-24.
6. Vincent FB, Bourke P, Morand EF, Mackay F, Bossingham D. Focus on systemic lupus erythematosus in Indigenous Australians: towards a better understanding of autoimmune diseases. Intern Med 2013;43:227-34.
7. Lahita RG. The role of sex hormones in systemic lupus erythematosus. Curr Opin Rheumatol 1999;11:352-56.
8. Feldt Von JM. Systemic lupus erythematosus. Recognizing its various presentations. Postgrad Med 1995;97:79, 83, 86 passim.
9. Fessler BJ, Boumpas DT. Severe major organ involvement in systemic lupus erythematosus. Diagnosis and management. Rheum Dis Clin North Am 1995;21:81-98.
10. Petri M, Orbai A-M, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64:2677-86.
11. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725.
12. Cronin ME. Musculoskeletal manifestations of systemic lupus erythematosus. Rheum Dis Clin North Am 1988;14:99-116.
13. Grossman JM. Lupus arthritis. Best Pract Res Clin Rheumatol 2009;23:495- 506.
14. van Vugt RM, Derksen RH, Kater L, Bijlsma JW. Deforming arthropathy or lupus and rhupus hands in systemic lupus erythematosus. Ann Rheum Dis 1998;57:540-44.
15. Walling HW, Sontheimer RD. Cutaneous lupus erythematosus: issues in diagnosis and treatment. Am J Clin Dermatol 2009;10:365-81.
16. Reddy BY, Hantash BM. Cutaneous connective tissue diseases: epidemiology, diagnosis, and treatment. Open Dermatol J 2009;3:22-31.
17. Provost TT. The relationship between discoid and systemic lupus erythematosus. Arch Dermatol 1994;130:1308-10.
18. Feldman CH, Hiraki LT, Liu J, et al. Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000-2004. Arthritis Rheum 2013;65:753-63.
19. Ortega LM, Schultz DR, Lenz O, Pardo V, Contreras GN. Review: Lupus nephritis: pathologic features, epidemiology and a guide to therapeutic decisions. Lupus 2010;19:557-74.
20. Sultan SM, Begum S, Isenberg DA. Prevalence, patterns of disease and outcome in patients with systemic lupus erythematosus who develop severe haematological problems. Rheumatology (Oxford). 2003;42:230-34.
21. Mittoo S, Gelber AC, Hitchon CA, et al. Clinical and serologic factors associated with lupus pleuritis. J Rheumatol 2010;37:747-53.
22. Cervera R, Khamashta MA, Font J, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. Medicine (Baltimore) 1993;72:113-24.
23. Tan EM, Feltkamp TE, Smolen JS, et al. Range of antinuclear antibodies in 'healthy' individuals. Arthritis Rheum 1997;40:1601-11.
24. Solomon DH, Kavanaugh AJ, Schur PH, American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines. Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum 2002;47:434-44.
25. Borgter EJ, Horst G, Hummel EJ, Limburg PC, Kallenberg CG. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum 1990;33:634-43.
26. Walport MJ. Complement and systemic lupus erythematosus. Arthritis Res 2002;4(Suppl 3):S279-93.
27. Marmor MF, Kellner U, Lai TY, Lyons JS, Mieler WF American Academy of Ophthalmology. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology 2011;118: 415-22.
28. Hahn BH. Belimumab for systemic lupus erythematosus. N Engl J Med 2013;368:1528-35.
29. Hahn BH. Systemic lupus erythematosus and accelerated atherosclerosis. N Engl J Med 2003;349:2379-80.